Boston Scientific Income taxes receivable decreased by 3.5% to $299.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 2.6%, from $307.00M to $299.00M. Over 5 years (FY 2020 to FY 2025), Income taxes receivable shows an upward trend with a 9.0% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase may indicate overpayment of estimated taxes or the accrual of refundable credits, representing a potential source of near-term cash inflow.
This represents the amount of income tax overpayments or refundable tax credits that the company expects to recover from...
Common for large corporations that manage complex tax filings across multiple jurisdictions.
income_taxes_receivable| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $202.00M | $217.00M | $205.00M | $249.00M | $264.00M | $262.00M | $264.00M | $296.00M | $303.00M | $307.00M | $315.00M | $319.00M | $315.00M | $332.00M | $307.00M | $294.00M | $298.00M | $310.00M | $299.00M |
| QoQ Change | — | +7.4% | -5.5% | +21.5% | +6.0% | -0.8% | +0.8% | +12.1% | +2.4% | +1.3% | +2.6% | +1.3% | -1.3% | +5.4% | -7.5% | -4.2% | +1.4% | +4.0% | -3.5% |
| YoY Change | — | — | — | — | +30.7% | +20.7% | +28.8% | +18.9% | +14.8% | +17.2% | +19.3% | +7.8% | +4.0% | +8.1% | -2.5% | -7.8% | -5.4% | -6.6% | -2.6% |